Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,644,749
  • Shares Outstanding, K 90,080
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,850 K
  • EBIT $ -108 M
  • EBITDA $ -108 M
  • 60-Month Beta -0.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.36

Options Overview Details

View History
  • Implied Volatility 96.26% (-43.33%)
  • Historical Volatility 183.48%
  • IV Percentile 18%
  • IV Rank 7.97%
  • IV High 573.79% on 10/24/25
  • IV Low 54.92% on 08/20/25
  • Expected Move (DTE 11) 3.94 (9.82%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 6,854
  • Volume Avg (30-Day) 2,659
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 44,232
  • Open Int (30-Day) 35,663
  • Expected Range 36.14 to 44.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.33
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.30 +119.02%
on 11/10/25
45.00 -10.93%
on 12/08/25
+21.61 (+117.00%)
since 11/07/25
3-Month
6.99 +473.80%
on 10/22/25
45.00 -10.93%
on 12/08/25
+32.80 (+450.55%)
since 09/08/25
52-Week
1.87 +2,049.06%
on 04/07/25
45.00 -10.93%
on 12/08/25
+33.53 (+511.91%)
since 12/06/24

Most Recent Stories

More News
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile...

TERN : 40.23 (+37.02%)
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of...

TERN : 40.23 (+37.02%)
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from...

TERN : 40.23 (+37.02%)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted...

TERN : 40.23 (+37.02%)
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host...

TERN : 40.23 (+37.02%)
5 Under-the-Radar Biotech Stocks That Could Soar in 2026

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

SLN : 6.91 (-0.72%)
CRDL : 1.0000 (-4.76%)
TERN : 40.23 (+37.02%)
INO : 2.09 (+0.97%)
TARA : 5.72 (+2.51%)
ATRA : 15.08 (+5.23%)
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants...

TERN : 40.23 (+37.02%)
Citizens JMP Remains a Buy on Terns Pharmaceuticals (TERN)

Citizens JMP analyst Silvan Tuerkcan reiterated a Buy rating on Terns Pharmaceuticals today and set a price target of $20.00. The company’s shares closed yesterday at $7.99.Elevate Your Investing Strategy:...

TERN : 40.23 (+37.02%)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...

TERN : 40.23 (+37.02%)
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...

TERN : 40.23 (+37.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY,...

See More

Key Turning Points

3rd Resistance Point 33.43
2nd Resistance Point 31.84
1st Resistance Point 30.60
Last Price 40.23
1st Support Level 27.77
2nd Support Level 26.18
3rd Support Level 24.94

See More

52-Week High 45.00
Last Price 40.23
Fibonacci 61.8% 28.52
Fibonacci 50% 23.43
Fibonacci 38.2% 18.34
52-Week Low 1.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar